Immuneering Corp

Listed Company

IMRXCIK 0001790340NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-56.02M

Total Assets

$231.99M

Equity

$218.48M

Shares Out

25.94M

Op. Cash Flow

$-45.34M

Business

Immuneering Corp is a clinical-stage oncology company developing small-molecule therapeutics that use Deep Cyclic Inhibition to target core signaling pathways, primarily the MAPK pathway. It offers orally administered MEK inhibitor product candidates, including lead programs IMM-1-104 (once-daily) and IMM-6-415 (twice-daily), alongside discovery programs targeting RAS and other oncology targets. Its key business activities include clinical development (Phase 1/2a trials), translational bioinformatics (Disease Cancelling Technology, Fluency) and proprietary human-aligned 3D tumor modeling. The company conducts clinical trials and regulatory interactions primarily in the United States and engages with pharmaceutical partners and global research collaborators for development and potential commercialization.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	42	48	42	36	27
General and administrative	17	16	17	16	8
Amortization of intangible asset	29,267	29,267	29,267	30,053	—
Total operating expenses	59	64	58	52	35
Loss from operations	−59	−64	−58	−52	−34
Interest income	3	3	4	1	169,899
Other income, net	311,665	441,493	1	216,844	−127,063
Net loss	−56	−61	−53	−51	−34
Net loss per share attributable to common stockholders, basic (in dollars per share)	−1.27	−2.04	−1.88	−1.91	−2.46
Net loss per share attributable to common stockholders, diluted (in dollars per share)	−1.27	−2.04	−1.88	−1.91	−2.46
Weighted-average common shares outstanding, basic (in shares)	44	30	28	26	14
Weighted-average common shares outstanding, diluted (in shares)	44	30	28	26	14
Unrealized gain from marketable securities	81,332	778	29,342	18,889	—
Comprehensive Loss	−56	−61	−53	−50	−34

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	129	36	59	73	75
Marketable securities, current	44	0	—	—	—
Prepaids and other current assets	3	3	3	3	3
Total current assets	176	40	89	109	152
Marketable securities, non-current	44	0	—	—	—
Property and equipment, net	938,481	1	1	1	807,223
Goodwill	7	7	7	7	7
Intangible asset, net	321,147	350,413	379,680	408,947	439,000
Right-of-use assets, net	3	4	4	4	5
Other assets	283,562	1	1	743,703	102,129
Total assets	232	53	103	122	167
Accounts payable	2	2	2	3	1
Accrued expenses	8	5	5	5	4
Other liabilities	291,513	233,665	259,770	19,796	—
Lease liabilities	397,104	338,438	300,107	378,723	274,039
Total current liabilities	10	8	8	8	6
Lease liabilities, net of current portion	3	4	4	4	5
Total liabilities	14	11	12	13	11
Commitments and contingencies (Note 11)	—	—	—	—	—
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; 0 shares issued or outstanding at December 31, 2025 and December 31, 2024	0	0	0	0	—
Additional paid-in capital	499	266	254	220	215
Accumulated other comprehensive income	81,332	0	−778	−30,120	−49,009
Accumulated deficit	−280	−224	−163	−110	−59
Total stockholders' equity	218	41	91	110	156
Total liabilities and stockholders' equity	232	53	103	122	167

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization expense	324,517	355,807	—	—	—
Reduction in carrying amount of right-of-use assets	345,103	328,377	412,055	519,541	113,605
Stock-based compensation expense	6	7	6	4	2
Net accretion of discount on marketable securities	−155,748	−259,181	−1	−171,382	—
Loss on disposal of fixed assets	2,093	6,784	3,939	5,170	—
Prepaid expenses and other current assets	491,837	−24,865	−172,660	−284,346	−2
Other assets	1	−261,337	−290,742	−360,200	—
Accounts payable	−400,799	−112,143	−1	2	−130,398
Accrued expenses	3	−200,831	721,989	474,568	3
Lease liabilities	−338,432	−300,102	−378,723	−126,382	−80,853
Other liabilities	57,848	−26,105	239,974	19,796	—
Net cash used in operating activities	−45	−55	−49	−44	−31
Purchases of property and equipment	−142,226	−84,875	−342,746	−742,483	−60,786
Purchases of marketable securities	−89	−5	−45	−50	−76
Maturities of marketable securities	0	32	52	93	—
Net cash (used in) provided by investing activities	−89	26	7	42	−76
Proceeds from exercise of stock options	368,532	732,458	444,838	300,379	354,434
Proceeds from employee stock purchase plan	421,910	374,652	0	—	—
Net cash provided by financing activities	227	5	28	19,004	144
Net increase (decrease) in cash and cash equivalents	93	−23	−13	−2	38
Deferred offering costs in accounts payable/accrued expenses	45,000	0	—	—	—
Cashless exercise of prefunded warrants	1,078	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro